Cumulus NeuroScience: Real-World Technology to Accelerate Clinical Trials in Dementia

据估计，到2025年，英国将有超过100万人患有痴呆症，2015年出生的人中有三分之一预计将在其一生中患上痴呆症（ARUK, www.dementiastatistics.org）。该领域的临床试验通常很长，药物开发成本极高，开发痴呆症治疗方法的成功率极低。对于参加正在进行或计划中的临床试验的数千名患者来说，至关重要的是，通过加快治疗途径，在药物开发人员的努力下，最大限度地发挥他们的宝贵贡献。BrainWaveBank目前的平台旨在提供一种健康技术解决方案，以支持药物机制的测量、治疗组的分层以及对治疗反应的早期检测。它包括一个易于使用的可穿戴耳机，以及在平板电脑上呈现的游戏，这些游戏可以测试认知的不同方面，产生基于大脑的神经生理机制和认知功能的生物标志物。在这个项目中，BrainWaveBank将在现有平台的基础上，对与痴呆症特别相关的更广泛领域进行综合、同步评估。提供一个单一的平台来统一临床试验的测量，以前会使用多种不同的工具来覆盖相同的领域，这将大大减轻患者的负担，最大限度地减少研究之间的差异，并大大减少药物开发人员的时间表和成本，最终导致更好地了解疾病，并更快地将有希望的治疗方法推向市场。

It is estimated that more than one million people in the UK will have dementia by 2025, with one in three born in 2015 projected to develop it in their lifetimes (ARUK, www.dementiastatistics.org). Clinical trials in this field are typically long, drug development costs are extremely high, and success rates for development of dementia treatments are exceedingly low. For many thousands of patients enrolled in ongoing or planned clinical trials, it is vital to maximise their valuable contribution alongside the efforts of drug developers by accelerating the path to treatment. BrainWaveBank's current platform is designed to provide a health technology solution to support measurement of drug mechanisms, stratification of treatment groups, and early detection of response to therapies. It consists of an easy-to-use, wearable headset, accompanied by games presented on a tablet that test different aspects of cognition, yielding brain-based biomarkers of neurophysiological mechanisms and cognitive function.In this project, BrainWaveBank will build upon their existing platform to incorporate integrated, synchronous assessment of a broader range of domains that are particularly relevant in dementia. Providing a single platform to unify measurements for clinical trials, where previously multiple different tools would have been used to cover the same ground, will significantly reduce patient burden, minimise variability across studies and dramatically reduce timelines and cost for drug developers, ultimately leading to a better understanding of disease and faster routes to market for promising treatments.